[{"id":"006e2786-ec9f-435c-b1a8-55c1b4f1678e","acronym":"PROTEOM","url":"https://clinicaltrials.gov/study/NCT04183569","created_at":"2021-01-18T20:23:47.835Z","updated_at":"2024-07-02T16:36:45.526Z","phase":"","brief_title":"Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04183569 - PROTEOM","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1","pipe":" | ","alterations":" CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation","tags":["BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 32","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-04-29"}]